Warner Chilcott Limited
Channel House Suite 3-105
Longfield Road Southside
St Davids,
Phone: 441-292-0068
Web Site: http://www.warnerchilcott.com
| Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women's healthcare and dermatology primarily in the United States. It offers various women healthcare products, including LOESTRIN 24 FE, OVCON 50, and FEMCON FE to prevent pregnancy; ESTROSTEP FE to prevent pregnancy and treat moderate acne in women, who desire oral contraception; FEMHRT 1/5 and .5/2.5 Oral to treat moderate to severe vasomotor symptoms and urogenital symptoms associated with menopause; and ESTRACE cream to treat vaginal and vulvar atrophy. The company also offers various dermatology products, such as TACLONEX and DOVONEX for the topical treatment of psoriasis; and DORYX, an oral adjunctive therapy for severe acne. In addition, its products under development include WC2061, an oral contraceptive, which is in a phase II pilot study; WC3016, an oral contraceptive that is in Phase III development stage; WC3026, an oral contraceptive which has completed Phase II stage; GD1105, a contraceptive vaginal ring that is in the preclinical phase; WC3018, which is in the preclinical phase for the treatment of acne and other inflammatory skin conditions; TD1414, a topical antibiotic for skin infections that is in late preclinical phase; WC2063, which is in the preclinical stage of development; LEO 80-185 that has completed Phase III to treat psoriasis of the scalp and body; LEO 80-190, which has completed Phase II stage for the topical treatment for psoriasis; and WC3027 that is in the preclinical phase for the treatment of inflammatory skin conditions. Its principal customers include wholesale pharmaceutical distributors, and major retail drug and grocery store chains. Warner Chilcott has license and supply agreement with LEO Pharma A/S. The company was founded in 1968 and is headquartered in Rockaway, New Jersey. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Mr. Roger M. Boissonneault , 59
Chief Exec. Officer, Pres
|
N/A
|
N/A |
Mr. Paul Herendeen , 52
Chief Financial Officer, Principal Accounting Officer and Exec. VP
|
N/A
|
N/A |
Mr. W. Carl Reichel , 49
Pres - Pharmaceuticals
|
N/A
|
N/A |
Ms. Izumi Hara , 48
Sr. VP, Gen. Counsel and Corp. Sec.
|
$
390.00K |
N/A |
Mr. Anthony Bruno , 52
Exec. VP of Corp. Devel.
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
0.375 (1.58%) 
Profile
